352 related articles for article (PubMed ID: 19897959)
1. Therapeutic options to modulate barrier defects in inflammatory bowel disease.
Hering NA; Schulzke JD
Dig Dis; 2009; 27(4):450-4. PubMed ID: 19897959
[TBL] [Abstract][Full Text] [Related]
2. Epithelial tight junctions in intestinal inflammation.
Schulzke JD; Ploeger S; Amasheh M; Fromm A; Zeissig S; Troeger H; Richter J; Bojarski C; Schumann M; Fromm M
Ann N Y Acad Sci; 2009 May; 1165():294-300. PubMed ID: 19538319
[TBL] [Abstract][Full Text] [Related]
3. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications.
Mankertz J; Schulzke JD
Curr Opin Gastroenterol; 2007 Jul; 23(4):379-83. PubMed ID: 17545772
[TBL] [Abstract][Full Text] [Related]
4. Disrupted barrier function through epithelial cell apoptosis.
Schulzke JD; Bojarski C; Zeissig S; Heller F; Gitter AH; Fromm M
Ann N Y Acad Sci; 2006 Aug; 1072():288-99. PubMed ID: 17057208
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.
Heller F; Florian P; Bojarski C; Richter J; Christ M; Hillenbrand B; Mankertz J; Gitter AH; Bürgel N; Fromm M; Zeitz M; Fuss I; Strober W; Schulzke JD
Gastroenterology; 2005 Aug; 129(2):550-64. PubMed ID: 16083712
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction.
Li Q; Zhang Q; Wang M; Zhao S; Ma J; Luo N; Li N; Li Y; Xu G; Li J
Clin Immunol; 2008 Jan; 126(1):67-80. PubMed ID: 17964857
[TBL] [Abstract][Full Text] [Related]
7. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
[TBL] [Abstract][Full Text] [Related]
8. The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption.
Ivanov AI; Nusrat A; Parkos CA
Novartis Found Symp; 2004; 263():115-24; discussion 124-32, 211-8. PubMed ID: 15669638
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.
Fischer A; Gluth M; Pape UF; Wiedenmann B; Theuring F; Baumgart DC
Am J Physiol Gastrointest Liver Physiol; 2013 Jun; 304(11):G970-9. PubMed ID: 23538493
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies.
Fries W; Muja C; Crisafulli C; Cuzzocrea S; Mazzon E
Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G938-47. PubMed ID: 18258792
[TBL] [Abstract][Full Text] [Related]
12. Cytokines in inflammatory bowel disease.
Kmieć Z
Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
[TBL] [Abstract][Full Text] [Related]
13. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease.
Shioya M; Nishida A; Yagi Y; Ogawa A; Tsujikawa T; Kim-Mitsuyama S; Takayanagi A; Shimizu N; Fujiyama Y; Andoh A
Clin Exp Immunol; 2007 Sep; 149(3):480-6. PubMed ID: 17590175
[TBL] [Abstract][Full Text] [Related]
14. Changes in the expression of claudins in active ulcerative colitis.
Oshima T; Miwa H; Joh T
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S146-50. PubMed ID: 19120888
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1.
Fischer A; Gluth M; Weege F; Pape UF; Wiedenmann B; Baumgart DC; Theuring F
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(3):G218-28. PubMed ID: 24309183
[TBL] [Abstract][Full Text] [Related]
16. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro.
Schroll S; Sarlette A; Ahrens K; Manns MP; Göke M
Regul Pept; 2005 Nov; 131(1-3):1-11. PubMed ID: 16122821
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease and the apical junctional complex.
Bruewer M; Samarin S; Nusrat A
Ann N Y Acad Sci; 2006 Aug; 1072():242-52. PubMed ID: 17057204
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation.
Ma TY; Iwamoto GK; Hoa NT; Akotia V; Pedram A; Boivin MA; Said HM
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G367-76. PubMed ID: 14766535
[TBL] [Abstract][Full Text] [Related]
19. Active and passive involvement of claudins in the pathophysiology of intestinal inflammatory diseases.
Barmeyer C; Fromm M; Schulzke JD
Pflugers Arch; 2017 Jan; 469(1):15-26. PubMed ID: 27904960
[TBL] [Abstract][Full Text] [Related]
20. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease.
Cantor MJ; Nickerson P; Bernstein CN
Am J Gastroenterol; 2005 May; 100(5):1134-42. PubMed ID: 15842590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
